TREA

87526706 - 420 THERAPEUTICS

Follow

Information

  • Trademark
  • 87526706
  • Serial Number
    87526706
  • Filing Date
    July 13, 2017
    7 years ago
  • Transaction Date
    August 28, 2018
    6 years ago
  • Status Date
    August 28, 2018
    6 years ago
  • Location Date
    August 28, 2018
    6 years ago
  • Status Code
    602
  • Current Location
    TMEG LAW OFFICE 109 - EXAMINING ATTORNEY ASSIGNED
    Employee Name
    STRUCK, ROBERT J
  • Attorney Name
    Avrom Warren Brown
    Law Office Assigned Location Code
    L90
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
420 THERAPEUTICS
Case File Statements
  • GS0051: Nutraceuticals for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis;pharmaceuticals and nutraceuticals containing cannabis, cannabinoids or cannabis compounds for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; prescription synthetic narcotics for medical use; pharmaceutical preparations for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; pharmaceutical preparations containing one or more cannabinoids as the active ingredient for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; medicines containing a tetrahydrocannabinol extract for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis;medicines derived from cannabis for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis
Case File Event Statements
  • 8/28/2018 - 6 years ago
    10 - ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Type: MAB2
  • 8/28/2018 - 6 years ago
    9 - ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Type: ABN2
  • 1/30/2018 - 6 years ago
    8 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 1/30/2018 - 6 years ago
    7 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 1/30/2018 - 6 years ago
    6 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 1/30/2018 - 6 years ago
    5 - REMOVED FROM TEAS PLUS Type: RFTP
  • 1/23/2018 - 6 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 8/1/2017 - 7 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 7/20/2017 - 7 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 7/17/2017 - 7 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP